Categories: BioTechCauseDevelopmentFinTechHealthTechInvestmentLabLivingTechnologyUniversity
ViewPoint Therapeutics is an early stage biotechnology company focused on the development of small molecule treatments for protein misfolding diseases, including cataracts and presbyopia.
Investors 4
Funding Rounds 2
| Date | Series | Amount | Investors |
| 05.03.2018 | Series B | $35M | - |
| 05.05.2016 | Series A | $4M | - |
Mentions in press and media 5
| Date | Title | Description |
| 12.03.2018 | Term Sheet — Monday, March 12 | SO LONG, VC
Good morning, Term Sheet readers.
Paid Content What you need to know about growing cyberattacks From ExtraHop
If you remember in January, Term Sheet reported that Arena Ventures, the Los Angeles-based early-stage venture capital... |
| 12.03.2018 | ViewPoint Therapeutics Raises $35M in Series B |
SAN FRANCISCO, CA, Privately-held biotechnology company pioneering the development of crystallin stabilizers announced the closing of a $35 million Series B financing.
>> Click here for more funding data on ViewPoint Therapeutics
... |
| 05.03.2018 | ViewPoint Therapeutics Raises $35 Million in Series B Financing | - |
| 06.05.2016 | ViewPoint Therapeutics Closes $4M Series A Financing | ViewPoint Therapeutics, Inc., a San Francisco, CA-based biotechnology company pioneering the development of crystallin stabilizers to prevent and treat cataracts and presbyopia, closed a $4m Series A financing.
The round was co-led by Missi... |
| 05.05.2016 | ViewPoint Therapeutics Raises $4 Million in Series A Financing | - |
Reviews 0
